Studies have shown that GPC-3 can be used as an immunotherapy target for HCC, and GPC-3-targeting monoclonal antibodies and GPC-3-targeting chimeric antigen receptor T cells (CAR-T) can effectively kill GPC-3-positive cells, including HCC tumor cells (5, 6). The gene discussed is GPC3; the disease is neoplasm.